Voriconazole dosing in children younger than 3 years undergoing cancer chemotherapy or hematopoietic stem cell transplantation

Shirley Qiong Yan, Brian Seyboth, Rachel Kobos, Anne Eaton, Susan K. Seo, Nina Cohen

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

There are limited pediatric population pharmacokinetic data for voriconazole dosing, particularly in younger children. In a cohort of 34 patients younger than 3 years receiving voriconazole, the majority (n = 23, 68%) had a low initial serum concentration <1 mg/L. Among 23 children <2 years old, 19 (83%) had an initial trough <1 mg/L. There was large intra- and interindividual variability in trough levels. Dosing also varied from 3.3 to 19.6 mg/kg per dose. Only 2 of 34 patients had a documented adverse drug reaction attributable to voriconazole. More data are needed to establish optimal dosing in very young children.

Original languageEnglish (US)
Pages (from-to)169-171
Number of pages3
JournalJournal of the Pediatric Infectious Diseases Society
Volume7
Issue number2
DOIs
StatePublished - 2018

Bibliographical note

Funding Information:
Financial support. This work was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Keywords

  • Children
  • Oncology
  • Pharmacokinetics
  • Voriconazole

Fingerprint Dive into the research topics of 'Voriconazole dosing in children younger than 3 years undergoing cancer chemotherapy or hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this